Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective

Aisling Barry; Smith Apisarnthanarax; Grainne M. O'Kane; Gonzalo Sapisochin; Robert Beecroft; Riad Salem; Sang Min Yoon; Young Suk Lim; John Bridgewater; Brian Davidson; Marta Scorsetti; Luigi Solbiati; Adam Diehl; Pablo Munoz Schuffenegger; Jonathan G. Sham; David Cavallucci; Zita Galvin; Laura A. Dawson; Maria A. Hawkins

doi:10.1016/S2468-1253(20)30182-5

Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective

Aisling Barry^*, Smith Apisarnthanarax, Grainne M. O'Kane, Gonzalo Sapisochin, Robert Beecroft, Riad Salem, Sang Min Yoon, Young Suk Lim, John Bridgewater, Brian Davidson, Marta Scorsetti, Luigi Solbiati, Adam Diehl, Pablo Munoz Schuffenegger, Jonathan G. Sham, David Cavallucci, Zita Galvin, Laura A. Dawson, Maria A. Hawkins

^*Corresponding author for this work

Radiology

Research output: Contribution to journal › Review article › peer-review

31 Scopus citations

Abstract

Around the world, recommendations for cancer treatment are being adapted in real time in response to the pandemic of COVID-19. We, as a multidisciplinary team, reviewed the standard management options, according to the Barcelona Clinic Liver Cancer classification system, for hepatocellular carcinoma. We propose treatment recommendations related to COVID-19 for the different stages of hepatocellular carcinoma (ie, 0, A, B, and C), specifically in relation to surgery, locoregional therapies, and systemic therapy. We suggest potential strategies to modify risk during the pandemic and aid multidisciplinary treatment decision making. We also review the multidisciplinary management of intrahepatic cholangiocarcinoma as a potentially curable and incurable diagnosis in the setting of COVID-19.

Original language	English (US)
Pages (from-to)	765-775
Number of pages	11
Journal	The Lancet Gastroenterology and Hepatology
Volume	5
Issue number	8
DOIs	https://doi.org/10.1016/S2468-1253(20)30182-5
State	Published - Aug 2020

Funding

RS is a consultant for Boston Scientific, Cook, Sirtex, Eisai, Genentech, and Becton Dickinson. PMS is on the Advanced Radiotherapy Committee for the International Association for the Study of Lung Cancer. LAD has a licensing agreement with Raysearch for image registration software in a system for radiation treatment planning. GMK is a consultant for Eisai. GS declares research funding from Roche and Bayer, outside the submitted work. AD declares funding from the Clinical Research Division at Fred Hutchinson Cancer Research Center, outside the submitted work. MAH and JB declare funding from the NIHR Biomedical Research Centre at University College London Hospitals National Health Service Foundation Trust, outside the submitted work. All other authors declare no competing interests.

ASJC Scopus subject areas

Hepatology
Gastroenterology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S2468-1253(20)30182-5

Cite this

Barry, A., Apisarnthanarax, S., O'Kane, G. M., Sapisochin, G., Beecroft, R., Salem, R., Yoon, S. M., Lim, Y. S., Bridgewater, J., Davidson, B., Scorsetti, M., Solbiati, L., Diehl, A., Schuffenegger, P. M., Sham, J. G., Cavallucci, D., Galvin, Z., Dawson, L. A., & Hawkins, M. A. (2020). Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective. The Lancet Gastroenterology and Hepatology, 5(8), 765-775. https://doi.org/10.1016/S2468-1253(20)30182-5

@article{63ddb50f399943a1823b4ae1a87ffff2,

title = "Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective",

abstract = "Around the world, recommendations for cancer treatment are being adapted in real time in response to the pandemic of COVID-19. We, as a multidisciplinary team, reviewed the standard management options, according to the Barcelona Clinic Liver Cancer classification system, for hepatocellular carcinoma. We propose treatment recommendations related to COVID-19 for the different stages of hepatocellular carcinoma (ie, 0, A, B, and C), specifically in relation to surgery, locoregional therapies, and systemic therapy. We suggest potential strategies to modify risk during the pandemic and aid multidisciplinary treatment decision making. We also review the multidisciplinary management of intrahepatic cholangiocarcinoma as a potentially curable and incurable diagnosis in the setting of COVID-19.",

author = "Aisling Barry and Smith Apisarnthanarax and O'Kane, {Grainne M.} and Gonzalo Sapisochin and Robert Beecroft and Riad Salem and Yoon, {Sang Min} and Lim, {Young Suk} and John Bridgewater and Brian Davidson and Marta Scorsetti and Luigi Solbiati and Adam Diehl and Schuffenegger, {Pablo Munoz} and Sham, {Jonathan G.} and David Cavallucci and Zita Galvin and Dawson, {Laura A.} and Hawkins, {Maria A.}",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Ltd",

year = "2020",

month = aug,

doi = "10.1016/S2468-1253(20)30182-5",

language = "English (US)",

volume = "5",

pages = "765--775",

journal = "The Lancet Gastroenterology and Hepatology",

issn = "2468-1253",

publisher = "Elsevier Ltd",

number = "8",

}

Barry, A, Apisarnthanarax, S, O'Kane, GM, Sapisochin, G, Beecroft, R, Salem, R, Yoon, SM, Lim, YS, Bridgewater, J, Davidson, B, Scorsetti, M, Solbiati, L, Diehl, A, Schuffenegger, PM, Sham, JG, Cavallucci, D, Galvin, Z, Dawson, LA & Hawkins, MA 2020, 'Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective', The Lancet Gastroenterology and Hepatology, vol. 5, no. 8, pp. 765-775. https://doi.org/10.1016/S2468-1253(20)30182-5

Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective. / Barry, Aisling; Apisarnthanarax, Smith; O'Kane, Grainne M. et al.
In: The Lancet Gastroenterology and Hepatology, Vol. 5, No. 8, 08.2020, p. 765-775.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Management of primary hepatic malignancies during the COVID-19 pandemic

T2 - recommendations for risk mitigation from a multidisciplinary perspective

AU - Barry, Aisling

AU - Apisarnthanarax, Smith

AU - O'Kane, Grainne M.

AU - Sapisochin, Gonzalo

AU - Beecroft, Robert

AU - Salem, Riad

AU - Yoon, Sang Min

AU - Lim, Young Suk

AU - Bridgewater, John

AU - Davidson, Brian

AU - Scorsetti, Marta

AU - Solbiati, Luigi

AU - Diehl, Adam

AU - Schuffenegger, Pablo Munoz

AU - Sham, Jonathan G.

AU - Cavallucci, David

AU - Galvin, Zita

AU - Dawson, Laura A.

AU - Hawkins, Maria A.

PY - 2020/8

Y1 - 2020/8

N2 - Around the world, recommendations for cancer treatment are being adapted in real time in response to the pandemic of COVID-19. We, as a multidisciplinary team, reviewed the standard management options, according to the Barcelona Clinic Liver Cancer classification system, for hepatocellular carcinoma. We propose treatment recommendations related to COVID-19 for the different stages of hepatocellular carcinoma (ie, 0, A, B, and C), specifically in relation to surgery, locoregional therapies, and systemic therapy. We suggest potential strategies to modify risk during the pandemic and aid multidisciplinary treatment decision making. We also review the multidisciplinary management of intrahepatic cholangiocarcinoma as a potentially curable and incurable diagnosis in the setting of COVID-19.

AB - Around the world, recommendations for cancer treatment are being adapted in real time in response to the pandemic of COVID-19. We, as a multidisciplinary team, reviewed the standard management options, according to the Barcelona Clinic Liver Cancer classification system, for hepatocellular carcinoma. We propose treatment recommendations related to COVID-19 for the different stages of hepatocellular carcinoma (ie, 0, A, B, and C), specifically in relation to surgery, locoregional therapies, and systemic therapy. We suggest potential strategies to modify risk during the pandemic and aid multidisciplinary treatment decision making. We also review the multidisciplinary management of intrahepatic cholangiocarcinoma as a potentially curable and incurable diagnosis in the setting of COVID-19.

UR - http://www.scopus.com/inward/record.url?scp=85086645374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85086645374&partnerID=8YFLogxK

U2 - 10.1016/S2468-1253(20)30182-5

DO - 10.1016/S2468-1253(20)30182-5

M3 - Review article

C2 - 32511951

AN - SCOPUS:85086645374

SN - 2468-1253

VL - 5

SP - 765

EP - 775

JO - The Lancet Gastroenterology and Hepatology

JF - The Lancet Gastroenterology and Hepatology

IS - 8

ER -

Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective

Abstract

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this